Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Oncopeptides in connection with a directed share issue (4)
Mandate

Vinge advises Oncopeptides in connection with a directed share issue

March 11, 2021 Capital Markets and Public M&A

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 1,106 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Carnegie, Cowen, DNB Markets, JP Morgan and Kempen & Co.

Oncopeptides is a clinical development pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström and Hampus Olsson.

 

Related

Vinge advises Axcel and Accru Partners in connection with the acquisitions of Baker Tilly Helsingborg AB, MOORE Allegretto AB and MOORE Ranby AB

 Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of Baker Tilly Helsingborg AB, MOORE Allegretto AB and MOORE Ranby AB.
September 18, 2025

Vinge advises Workday, Inc. on its $1.1 billion acquisition of Sana Labs

 Vinge, together with Orrick Herrington & Sutcliffe, has advised Workday, Inc. (NASDAQ: WDAY) (“Workday”) on its acquisition of all shares in Sana Labs AB.
September 16, 2025

Vinge advises on the sale of ArmaTech to Defensor Group

 Vinge has advised on the sale of ArmaTech i Kungsbacka AB (“ArmaTech”) to the newly formed defence group Defensor Group AB (“Defensor”).
September 16, 2025